News & Updates

Self-reported adverse reactions less likely after inactivated CZ02 vs mRNA-based BNT162b2
Self-reported adverse reactions less likely after inactivated CZ02 vs mRNA-based BNT162b2
23 Feb 2022
Knowing someone with COVID-19 a key predictor of vaccine uptake among HK adolescents
Knowing someone with COVID-19 a key predictor of vaccine uptake among HK adolescents
23 Feb 2022
Hypertension in pregnancy: Labetalol extends benefits for pregnancy outcomes
Hypertension in pregnancy: Labetalol extends benefits for pregnancy outcomes
22 Feb 2022 byJairia Dela Cruz

Common blood pressure (BP)-lowering medications in pregnancy cut the risk of severe hypertension, but labetalol has the added advantage of reducing the risks of proteinuria or pre-eclampsia and perinatal death, according to the results of a network meta-analysis.

Hypertension in pregnancy: Labetalol extends benefits for pregnancy outcomes
22 Feb 2022
First-line biologic therapy persists longer than later agents in ankylosing spondylitis
First-line biologic therapy persists longer than later agents in ankylosing spondylitis
22 Feb 2022

Biologic disease-modifying antirheumatic drug (bDMARD) therapy is effective in reducing ankylosing spondylitis (AS) disease activity, reports a study, noting how treatment has persisted for up to 8 years among patients remaining on their first bDMARD, which is longer than on subsequent agents.

First-line biologic therapy persists longer than later agents in ankylosing spondylitis
22 Feb 2022